Eleva Revenue and Competitors
Estimated Revenue & Valuation
- Eleva's estimated annual revenue is currently $4.5M per year.
- Eleva's estimated revenue per employee is $155,000
Employee Data
- Eleva has 29 Employees.
- Eleva grew their employee count by 7% last year.
Eleva's People
Name | Title | Email/Phone |
---|
Eleva Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Eleva?
Based in Freiburg, Germany, Eleva develops novel biological therapies with its pharmaceutical partners. The privately-held company leverages its unique moss-based production platform to produce supreme biologics like antibodies, replacement enzymes, or fusion toxins. Eleva has successfully developed drug candidates into clinical phases. Impressum: https://www.elevabiologics.com/contact/imprint/
keywords:N/AN/A
Total Funding
29
Number of Employees
$4.5M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Eleva News
Camioneros siguen movilizados. Hoy se trataría proyecto que eleva pena por cierres de rutas. 21 abril, 2022...
Alexa Dellanos eleva la temperatura con escotado vestido semitransparente sin sostén · Alexa Dellanos se animó a desafiar la censura de Instagram...
Plant-based Biologics and Expression Systems Global Market Report 2022: Profiles of Medicago, Leaf Expression Systems, Eleva, iBIO,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.9M | 29 | 32% | N/A |
#2 | $5M | 30 | -3% | N/A |
#3 | $3.7M | 32 | N/A | N/A |
#4 | N/A | 36 | 57% | N/A |
#5 | $10M | 38 | 41% | N/A |